# EDGAR Filing Document

**Accession Number:** 0001648257
**File Stem:** 0001648257-26-000017
**Filing Date:** 2026-3
**Character Count:** 12742
**Document Hash:** 5f446db65faa3ff8679de2bf9efef1ad
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001648257-26-000017.hdr.sgml**: 20260311

**ACCESSION NUMBER**: 0001648257-26-000017

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260311

**FILED AS OF DATE**: 20260311

**DATE AS OF CHANGE**: 20260311

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HUTCHMED (China) Ltd
- **CENTRAL INDEX KEY:** 0001648257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37710
- **FILM NUMBER:** 26741445

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3
- **BUSINESS PHONE:** 852-2121-3888

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hutchison China MediTech Ltd
- **DATE OF NAME CHANGE:** 20150716

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 6-K**

------

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the Month of March 2026**

**Commission File Number: 001-37710**

------

**HUTCHMED (CHINA) LIMITED**

(Translation of registrant's name into English)

------

**48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong**

(Address of principal executive offices)

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ◻

------

**HUTCHMED (CHINA) LIMITED**

**Form 6-K**

<u>EXHIBIT INDEX</u>

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| Exhibit 99.1 | Announcement relating to vesting of awards under the long term incentive plan |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| HUTCHMED (CHINA) LIMITED | HUTCHMED (CHINA) LIMITED |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |

---

Date: March 11, 2026

------

## Exhibit 99.1

**Exhibit 99.1**

![Graphic](hcm-20260311xex99d1001.gif)

**Vesting of awards under the Long Term Incentive Plan**

**Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 11, 2026:** HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2025 annual results of HUTCHMED on March 5, 2026, the following awards granted under the Long Term Incentive Plan ("LTIP") on June 5, 2023 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 10, 2026:-

---

| | |
|:---|:---|
| Award Holders | Number of ordinary shares |
| &nbsp;&nbsp;**Person Discharging Managerial Responsibilities** | &nbsp;&nbsp;**Person Discharging Managerial Responsibilities** |
| Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) | 524079 |
| Mr Johnny Cheng (Executive Director, Acting Chief Executive Officer and Chief Financial Officer) | 202238 |
| **Total** | 726317 |

---

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

------

&nbsp;&nbsp;&nbsp;&nbsp;**(a)** **Dr Weiguo Su** 

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Name | &nbsp;&nbsp;<br>Dr Weiguo Su | &nbsp;&nbsp;<br>Dr Weiguo Su |
| &nbsp;&nbsp;**2**  | &nbsp;&nbsp;**Reason for the notification**  | &nbsp;&nbsp;**Reason for the notification**  | &nbsp;&nbsp;**Reason for the notification**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Position/status | &nbsp;&nbsp;<br>Executive Director, Chief Executive Officer and Chief Scientific Officer  | &nbsp;&nbsp;<br>Executive Director, Chief Executive Officer and Chief Scientific Officer  |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>Initial notification/Amendment | &nbsp;&nbsp;<br>Initial notification | &nbsp;&nbsp;<br>Initial notification |
| &nbsp;&nbsp;**3**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Name | &nbsp;&nbsp;<br>HUTCHMED (China) Limited | &nbsp;&nbsp;<br>HUTCHMED (China) Limited |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>LEI | &nbsp;&nbsp;<br>2138006X34YDQ6OBYE79 | &nbsp;&nbsp;<br>2138006X34YDQ6OBYE79 |
| &nbsp;&nbsp;**4**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Description of the financial instrument, type of instrument<br>Identification code | &nbsp;&nbsp;<br>Ordinary Shares of US$0.10<br>Ordinary Share with DI ISIN: KYG4672N1016 | &nbsp;&nbsp;<br>Ordinary Shares of US$0.10<br>Ordinary Share with DI ISIN: KYG4672N1016 |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>Nature of the transaction | &nbsp;&nbsp;<br>Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP | &nbsp;&nbsp;<br>Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) | &nbsp;&nbsp;**Price(s)** | &nbsp;&nbsp;**Volume(s)** |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) | &nbsp;&nbsp;Nil | &nbsp;&nbsp;524,079 ordinary shares |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;<br>d) | &nbsp;&nbsp;<br>Aggregated information<br>— Aggregated volume<br>— Price | &nbsp;&nbsp;<br>N/A  | &nbsp;&nbsp;<br>N/A  |
| &nbsp;&nbsp;<br>e) | &nbsp;&nbsp;<br>Date of the transaction | &nbsp;&nbsp;<br>2026-03-10 | &nbsp;&nbsp;<br>2026-03-10 |
| &nbsp;&nbsp;<br>f) | &nbsp;&nbsp;<br>Place of the transaction | &nbsp;&nbsp;<br>Outside a trading venue | &nbsp;&nbsp;<br>Outside a trading venue |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;**(b)** **Mr Johnny Cheng** 

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Name | &nbsp;&nbsp;<br>Mr Johnny Cheng | &nbsp;&nbsp;<br>Mr Johnny Cheng |
| &nbsp;&nbsp;**2**  | &nbsp;&nbsp;**Reason for the notification**  | &nbsp;&nbsp;**Reason for the notification**  | &nbsp;&nbsp;**Reason for the notification**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Position/status | &nbsp;&nbsp;<br>Executive Director, Acting Chief Executive Officer and Chief Financial Officer  | &nbsp;&nbsp;<br>Executive Director, Acting Chief Executive Officer and Chief Financial Officer  |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>Initial notification/Amendment | &nbsp;&nbsp;<br>Initial notification | &nbsp;&nbsp;<br>Initial notification |
| &nbsp;&nbsp;**3**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  | &nbsp;&nbsp;**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Name | &nbsp;&nbsp;<br>HUTCHMED (China) Limited | &nbsp;&nbsp;<br>HUTCHMED (China) Limited |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>LEI | &nbsp;&nbsp;<br>2138006X34YDQ6OBYE79 | &nbsp;&nbsp;<br>2138006X34YDQ6OBYE79 |
| &nbsp;&nbsp;**4**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  | &nbsp;&nbsp;**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**  |
| &nbsp;&nbsp;<br>a) | &nbsp;&nbsp;<br>Description of the financial instrument, type of instrument<br>Identification code | &nbsp;&nbsp;<br>Ordinary Shares of US$0.10<br>Ordinary Share with DI ISIN: KYG4672N1016 | &nbsp;&nbsp;<br>Ordinary Shares of US$0.10<br>Ordinary Share with DI ISIN: KYG4672N1016 |
| &nbsp;&nbsp;<br>b) | &nbsp;&nbsp;<br>Nature of the transaction | &nbsp;&nbsp;<br>Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP | &nbsp;&nbsp;<br>Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) | &nbsp;&nbsp;**Price(s)** | &nbsp;&nbsp;**Volume(s)** |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) | &nbsp;&nbsp;Nil | &nbsp;&nbsp;202,238 ordinary shares |
| &nbsp;&nbsp;<br>c) | &nbsp;&nbsp;<br>Price(s) and volume(s) |  |  |
| &nbsp;&nbsp;<br>d) | &nbsp;&nbsp;<br>Aggregated information<br>— Aggregated volume<br>— Price<br>| &nbsp;&nbsp;<br>N/A  | &nbsp;&nbsp;<br>N/A  |
| &nbsp;&nbsp;<br>e) | &nbsp;&nbsp;<br>Date of the transaction | &nbsp;&nbsp;<br>2026-03-10 | &nbsp;&nbsp;<br>2026-03-10 |
| &nbsp;&nbsp;<br>f) | &nbsp;&nbsp;<br>Place of the transaction | &nbsp;&nbsp;<br>Outside a trading venue | &nbsp;&nbsp;<br>Outside a trading venue |

---

#### About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

------

**CONTACTS**

---

| | |
|:---|:---|
| **Investor Enquiries** | +852 2121 8200 / ir@hutch-med.com |
| **Media Enquiries** |  |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ben Atwell / Tim Stamper | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| **Panmure Liberum** | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden  | +44 20 7886 2500 |
| **Cavendish** | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| **Deutsche Numis** | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |

---

------